These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 22019206

  • 1. Nafamostat mesilate, as a treatment for heparin resistance, is not associated with perioperative ischemic stroke in patients undergoing cardiac surgery with cardiopulmonary bypass.
    Kikura M, Tanaka K, Hiraiwa T, Tanaka K.
    J Cardiothorac Vasc Anesth; 2012 Apr; 26(2):239-44. PubMed ID: 22019206
    [Abstract] [Full Text] [Related]

  • 2. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
    Kaminishi Y, Hiramatsu Y, Watanabe Y, Yoshimura Y, Sakakibara Y.
    Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
    [Abstract] [Full Text] [Related]

  • 3. Cardiopulmonary bypass strategy with low-dose heparin and nafamostat mesilate in cardiac surgery: a safe option for patients with acute stroke.
    Morimoto N, Henmi S, Yoshida M, Mukohara N.
    J Thorac Cardiovasc Surg; 2012 Sep; 144(3):726-8. PubMed ID: 22541513
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy of nafamostat mesilate as anticoagulation during cardiopulmonary bypass for early surgery in patients with active infective endocarditis complicated by stroke.
    Sakamoto T, Kano H, Miyahara S, Inoue T, Izawa N, Gotake Y, Matsumori M, Okada K, Okita Y.
    J Heart Valve Dis; 2014 Nov; 23(6):744-51. PubMed ID: 25790622
    [Abstract] [Full Text] [Related]

  • 5. Nafamostat mesilate reduces blood loss during open heart surgery.
    Murase M, Usui A, Tomita Y, Maeda M, Koyama T, Abe T.
    Circulation; 1993 Nov; 88(5 Pt 2):II432-6. PubMed ID: 8222190
    [Abstract] [Full Text] [Related]

  • 6. Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?
    Park KT, Kang DH, Choi CW, Cho M, Park SB, Kim HW, Kim DU, Chung CW, Yoon KT.
    Pancreas; 2011 Nov; 40(8):1215-9. PubMed ID: 21775918
    [Abstract] [Full Text] [Related]

  • 7. Cardiopulmonary bypass using nafamostat mesilate for patients with infective endocarditis and recent intracranial hemorrhage.
    Ota T, Okada K, Kano H, Okita Y.
    Interact Cardiovasc Thorac Surg; 2007 Jun; 6(3):270-3. PubMed ID: 17669840
    [Abstract] [Full Text] [Related]

  • 8. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy.
    Hwang SD, Hyun YK, Moon SJ, Lee SC, Yoon SY.
    Int J Artif Organs; 2013 Mar; 36(3):208-16. PubMed ID: 23404639
    [Abstract] [Full Text] [Related]

  • 9. Outcomes of extracorporeal life support for low cardiac output syndrome after major cardiac surgery.
    Park SJ, Kim JB, Jung SH, Choo SJ, Chung CH, Lee JW.
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):283-9. PubMed ID: 23219332
    [Abstract] [Full Text] [Related]

  • 10. [Effect of nafamostat mesilate on serum activities of pancreatic enzymes and plasma hormone levels].
    Wakayama S, Suzuki T, Sakai T, Matsuki A.
    Masui; 1990 Jun; 39(6):734-40. PubMed ID: 2388392
    [Abstract] [Full Text] [Related]

  • 11. [Experimental study on heparin-free cardiopulmonary bypass using nafamostat mesilate (FUT-175) and heparin-coated circuit].
    Takano H, Miyamoto Y, Kaneko M, Matsuwaka R, Kuratani T, Amemiya A, Nakano S, Matsuda H.
    Nihon Kyobu Geka Gakkai Zasshi; 1993 Nov; 41(11):2166-73. PubMed ID: 8283086
    [Abstract] [Full Text] [Related]

  • 12. Nafamostat mesilate reduces blood-foreign surface reactions similar to biocompatible materials.
    Usui A, Hiroura M, Kawamura M, Hibi M, Yoshida K, Murakami F, Tomita Y, Ooshima H, Murase M.
    Ann Thorac Surg; 1996 Nov; 62(5):1404-11. PubMed ID: 8893576
    [Abstract] [Full Text] [Related]

  • 13. Refractory chronic urticaria treated effectively with the protease inhibitors, nafamostat mesilate and camostat mesilate.
    Takahagi S, Shindo H, Watanabe M, Kameyoshi Y, Hide M.
    Acta Derm Venereol; 2010 Jul; 90(4):425-6. PubMed ID: 20574618
    [No Abstract] [Full Text] [Related]

  • 14. Perioperative renal outcome in cardiac surgical patients with preoperative renal dysfunction: aprotinin versus epsilon aminocaproic acid.
    Maslow AD, Chaudrey A, Bert A, Schwartz C, Singh A.
    J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):6-15. PubMed ID: 18249324
    [Abstract] [Full Text] [Related]

  • 15. Attenuation of cardiopulmonary bypass-derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations.
    Sawa Y, Shimazaki Y, Kadoba K, Masai T, Fukuda H, Ohata T, Taniguchi K, Matsuda H.
    J Thorac Cardiovasc Surg; 1996 Jan; 111(1):29-35. PubMed ID: 8551786
    [Abstract] [Full Text] [Related]

  • 16. Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study.
    Sawada K, Ohdo M, Ino T, Nakamura T, Numata T, Shibata H, Sakou J, Kusada M, Hibi T.
    Ther Apher Dial; 2016 Apr; 20(2):197-204. PubMed ID: 26771066
    [Abstract] [Full Text] [Related]

  • 17. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
    Pleym H, Videm V, Wahba A, Asberg A, Amundsen T, Bjella L, Dale O, Stenseth R.
    Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.